0000000000326032

AUTHOR

M. Natali

showing 4 related works from this author

Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phas…

1996

Purpose : To compare mitomycin C plus vindesine plus etoposide (MEV) vs. mitomycin C plus vindesine plus cisplatin (MVP) in the treatment of stage IV non-small-cell lung cancer. Patients and methods : 204 patients were entered in a phase III multicentre randomised trial from June 1990 to December 1994 and stratified according to the ECOG performance status (0-1 vs. 2). MVP was given in the following dosages : mitomycin C 8 mg/m 2 + vindesine 3 mg/m 2 + cisplatin 100 mg/m 2 i.v. day 1 and vindesine 3 mg/m 2 i.v. day 8 with cycles repeated every 4 weeks. MEV was given in the following dosages : mitomycin C 8 mg/m 2 + vindesine 3 mg/m 2 i.v. day I and etoposide 100 mg/m 2 i.v. days 1 to 3 with…

Chemotherapymedicine.medical_specialtyPalliative carePerformance statusbusiness.industrymedicine.medical_treatmentMitomycin CHematologymedicine.diseaseGastroenterologyOncologyInternal medicinemedicineVindesineNuclear medicinebusinessLung cancerSurvival rateEtoposidemedicine.drug
researchProduct

Age and case mix-standardised survival for all cancer patients in Europe 1999-2007: Results of EUROCARE-5, a population-based study

2015

Background: Overall survival after cancer is frequently used when assessing a health care service’s performance as a whole. It is mainly used by the public, politicians and the media, and is often dismissed by clinicians because of the heterogeneous mix of different cancers, risk factors and treatment modalities. Here we give survival details for all cancers combined in Europe, correlating it with economic variables to suggest reasons for differences. Methods: We computed age and cancer site case- mix standardised relative survival for all cancers combined (ACRS) for 29 countries participating in the EUROCARE-5 project with data on more than 7.5 million cancer cases from 87 population-based…

Cancer ResearchPopulationPopulation-based cancer registrieAll cancerGross domestic productCase-mix by cancer siteCase mix indexHealth careMedicineeducationMETIS-311842education.field_of_studyRelative survivalbusiness.industryCancerCancer survivalPopulation-based cancer registriesmedicine.diseaseCancer survivalEastern europeanOncologyAll cancer ; Cancer survival ; Case-mix by cancer site ; EUROCARE ; Population-based cancer registriesbusinessEUROCAREIR-97293Demography
researchProduct

Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival esti…

2017

Abstract Background Cancer registries (CRs) are fundamental for estimating cancer burden, evaluating screening and monitoring health service performance. Stage at diagnosis—an essential information item collected by CRs—has been made available, for the first time, by CRs participating in EUROCARE-5. We analysed the quality of this information and estimated stage-specific survival across Europe for CRs with good data quality. Data and methods Sixty-two CRs sent stage (as TNM, condensed TNM or extent of disease) for 15 cancers diagnosed in 2000–2007. We assessed the quality, partly by comparing stage according to the three systems. We also developed procedures to reconstruct stage (categories…

Malemedicine.medical_specialtyCancer ResearchStage at diagnosiSurvivalConcordanceCancer registrieCancer registries ; Data quality ; Stage at diagnosis ; SurvivalSocio-culturaleReproducibility of ResultPredictive Value of TestCancer registries; Data quality; Stage at diagnosis; Survival; Data Accuracy; Europe; Female; Humans; Male; Neoplasm Metastasis; Neoplasms; Predictive Value of Tests; Reproducibility of Results; Survival Analysis; Neoplasm Staging; Registries; Oncology; Cancer Research03 medical and health sciences0302 clinical medicineBreast cancerPredictive Value of TestsNeoplasmsmedicineotorhinolaryngologic diseasesCancer registriesHumans030212 general & internal medicineRegistriesStage (cooking)Neoplasm MetastasisIntensive care medicineSurvival analysisCancer stagingNeoplasm Stagingbusiness.industryData qualityReproducibility of ResultsStage at diagnosismedicine.diseaseSurvival AnalysisCancer registryData AccuracyClinical trialNeoplasm MetastasiEuropeOncology030220 oncology & carcinogenesisData qualityNeoplasmFemaleSurvival AnalysibusinessHumanEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Italian cancer figures, report 2014: Prevalence and cure of cancer in Italy

2015

This Report intends to estimate the total number of people still alive in 2010 after cancer diagnosis in Italy, regardless of the time since diagnosis, and to project these estimates to 2015. This study is also aimed to estimate the number of already cured cancer patients, whose mortality rates have become undistinguishable from that of the general population of the same age and sex.The study took advantage of the information from the AIRTUM database, which included 29 Cancer Registries (covering 21 million people, 35% of the Italian population). A total of 1,624,533 cancer cases diagnosed between 1976 and 2009 contributed to the study. For each registry, the observed prevalence was calcula…

Aged 80 and overMaleMedicine (all)Aged; Aged 80 and over; Female; Humans; Italy; Male; Middle Aged; Neoplasms; Prevalence; Registries; Survival RateSocio-culturaleMiddle AgedSettore MED/42 - Igiene Generale E ApplicataSurvival RateItalyNeoplasms80 and overPrevalenceHumanscancer prevalence cancer incidence cancer in ItalyFemaleRegistriesAged
researchProduct